Fineline Cube

Follow:
14778 Articles
Jiaxing Faber Xintian Pharma Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion
CompanyDeals

Jiaxing Pharbers Genesis Secures RMB 100 Million in Series A2 Financing for Radiopharmaceuticals Expansion

Novo Holdings' Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion
CompanyDeals

Novo Holdings’ Acquisition of Catalent Gets EU Nod, Paving Way for Novo Nordisk Expansion

Johnson & Johnson's Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
CompanyDrug

Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024

AstraZeneca's Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC
CompanyDrug

AstraZeneca’s Imfinzi Demonstrates Positive Outcomes in PACIFIC-5 III Study for NSCLC

Duality Biologics' BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia
CompanyDrug

Duality Biologics’ BNT324/DB-1311 Shows Positive Results in Global Phase I/IIa Study at ESMO Asia

Innovent Biologics' IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia
CompanyDrug

Innovent Biologics’ IBI343 Shows Promising Results in Phase I Study for Pancreatic Cancer at ESMO Asia

Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals' Nutritional Products in China
CompanyDeals

Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals’ Nutritional Products in China

Novartis' Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study
CompanyDrug

Novartis’ Scemblix Demonstrates Superior MMR Rates in Phase III ASC4FIRST Study

Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
CompanyDrug

Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials

SinoPep-Allsino Biopharmaceutical Partners with Spraying Systems Co. for Peptide API Manufacturing
CompanyDeals

SinoPep-Allsino Biopharmaceutical Partners with Spraying Systems Co. for Peptide API Manufacturing

Merck's Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
CompanyDrug

Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation

Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange
CompanyDeals

Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange